Results 1 to 10 of about 674,512 (170)

Chinese Prostate Cancer Consortium (CPCC) Chinese expert consensus on advanced prostate cancer: clinical management of patients with metastatic hormone-sensitive prostate cancer treated by initial novel hormone therapy (2022 edition) [PDF]

Zhongguo aizheng zazhi, 2022
Metastatic hormone-sensitive prostate cancer (mHSPC) is a male health concern requiring continuous attention. In 2021, an important update was included in domestic and international guidelines regarding the recommendations of initial systemic therapy for
Chinese Prostate Cancer Consortium (CPCC), YE Dingwei, HUANG Jian
doaj   +1 more source

Examining the influence of illness perception and financial toxicity on the quality of life of prostate cancer patients

African Journal of Urology, 2021
Background Cancer of the prostate (CaP) is a public health problem that affects the male genitourinary system causing a significant threat to men’s quality of life (QoL).
Elizabeth O. Akin-Odanye, Chidiebere N. Ogo, Faoziyat A. Sulaiman, Lawal Suleiman, Motolani E. Ogunsanya, Folakemi T. Odedina   +5 more
doaj   +1 more source

The relationship between biochemical recurrence and number of lymph nodes removed during surgery for localized prostate cancer

BMC Urology, 2023
Purpose To assess whether completeness of pelvic lymph node dissection (PLND) as measured by lymph node yield reduces biochemical recurrence (BCR) in men undergoing radical prostatectomy (RP) for prostate cancer (PCa), stratified according to Briganti ...
Paul Doan, Athos Katelaris, Matthijs J. Scheltema, Andrew Hayen, Amer Amin, Amila Siriwardana, Minh Tran, Bart Geboers, William Gondoputro, Anne Maree Haynes, Jayne Matthews, Warick Delprado, Phillip D. Stricker, James Thompson   +13 more
doaj   +1 more source

Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen

The World Journal of Men's Health, 2023
Purpose: Prostate cancer (PCa) screening can lead to potential over-diagnosis/over-treatment of indolent cancers. There is a need to optimize practices to better risk-stratify patients.
Zoe D. Michael, Srinath Kotamarti, Rohith Arcot, Kostantinos Morris, Anand Shah, John Anderson, Andrew J. Armstrong, Rajan T. Gupta, Steven Patierno, Nadine J. Barrett, Daniel J. George, Glenn M. Preminger, Judd W. Moul, Kevin C. Oeffinger, Kevin Shah, Thomas J. Polascik   +15 more
doaj   +1 more source

Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes

BMC Urology, 2022
Background To report the feasibility, oncological and functional outcomes of salvage robot-assisted radical prostatectomy (sRARP) for recurrent prostate cancer (PCa) after irreversible electroporation (IRE).
Alexandar Blazevski, William Gondoputro, Matthijs J. Scheltema, Amer Amin, Bart Geboers, Daniela Barreto, Anne-Maree Haynes, Ron Shnier, Warick Delprado, Shikha Agrawal, James E. Thompson, Phillip D. Stricker   +11 more
doaj   +1 more source

Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea

BMC Cancer, 2018
Background For the expanding population of bladder cancer survivors in Korea, the development of subsequent cancers is a significant concern. Here, we provide the second primary cancer incidence rates and types in Korean patients with bladder cancer ...
Whi-An Kwon, Jae Young Joung, Jiwon Lim, Chang-Mo Oh, Kyu-Won Jung, Sung Han Kim, Ho Kyung Seo, Weon Seo Park, Jinsoo Chung, Kang Hyun Lee, Young-Joo Won   +10 more
doaj   +1 more source

HIF1 and ID1 Interplay Confers Adaptive Survival to HIF1α-Inhibition

Frontiers in Cell and Developmental Biology, 2021
Hypoxia is a universal pathological feature of solid tumors. Hypoxic tumor cells acquire metastatic and lethal phenotypes primarily through the activities of hypoxia-inducible factor 1 alpha (HIF1α).
Hao Geng, Hyun-Kyung Ko, Janet Pittsenbarger, Christopher T. Harvey, Changhui Xue, Qiong Liu, Sadie Wiens, Sushant K. Kachhap, Tomasz M. Beer, David Z. Qian   +9 more
doaj   +1 more source

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma

Genome Medicine, 2019
Background Malignant peritoneal mesothelioma (PeM) is a rare and fatal cancer that originates from the peritoneal lining of the abdomen. Standard treatment of PeM is limited to cytoreductive surgery and/or chemotherapy, and no effective targeted ...
Raunak Shrestha, Noushin Nabavi, Yen-Yi Lin, Fan Mo, Shawn Anderson, Stanislav Volik, Hans H. Adomat, Dong Lin, Hui Xue, Xin Dong, Robert Shukin, Robert H. Bell, Brian McConeghy, Anne Haegert, Sonal Brahmbhatt, Estelle Li, Htoo Zarni Oo, Antonio Hurtado-Coll, Ladan Fazli, Joshua Zhou, Yarrow McConnell, Andrea McCart, Andrew Lowy, Gregg B. Morin, Tianhui Chen, Mads Daugaard, S. Cenk Sahinalp, Faraz Hach, Stephane Le Bihan, Martin E. Gleave, Yuzhuo Wang, Andrew Churg, Colin C. Collins   +32 more
doaj   +1 more source

Small extracellular vesicle-mediated ITGB6 siRNA delivery downregulates the αVβ6 integrin and inhibits adhesion and migration of recipient prostate cancer cells

Cancer Biology & Therapy, 2022
The αVβ6 integrin, an epithelial-specific cell surface receptor absent in normal prostate and expressed during prostate cancer (PrCa) progression, is a therapeutic target in many cancers.
Shiv Ram Krishn, Vaughn Garcia, Nicole M. Naranjo, Fabio Quaglia, Christopher D. Shields, Maisha A. Harris, Andrew V. Kossenkov, Qin Liu, Eva Corey, Dario C. Altieri, Lucia R. Languino   +10 more
doaj   +1 more source

Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours

BMC Cancer, 2018
Background Bleomycin, etoposide, and cisplatin (BEP) chemotherapy administered every 3 weeks for 4 cycles remains the standard first line treatment for patients with intermediate- and poor-risk metastatic germ cell tumours (GCTs).
Nicola J. Lawrence, Howard Chan, Guy Toner, Martin R. Stockler, Andrew Martin, Sonia Yip, Nicole Wong, Annie Yeung, Danish Mazhar, Farzana Pashankar, Lindsay Frazier, Ray McDermott, Roderick Walker, Hsiang Tan, Ian D. Davis, Peter Grimison, on behalf of ANZUP   +16 more
doaj   +1 more source